Logo Logo
Switch Language to German
Boeck, S.; Jung, A.; Laubender, Rüdiger P.; Neumann, J.; Egg, R.; Goritschan, C.; Ormanns, S.; Haas, M.; Modest, D. P.; Kirchner, T.; Heinemann, V. (2013): KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer. In: Journal of Gastroenterology, Vol. 48, No. 4: pp. 544-548
Full text not available from 'Open Access LMU'.